Cover Image


Biomarkers in Alzheimer's Disease

出版商 Insight Pharma Reports 商品編碼 308694
出版日期 內容資訊 英文 95 Pages
Back to Top
老年癡呆症的生物標記 Biomarkers in Alzheimer's Disease
出版日期: 2014年07月23日 內容資訊: 英文 95 Pages



第1章 本報告的焦點

第2章 生物標記與其臨床性利用性

  • 所謂生物標記
  • 生物標記的優點
  • 臨床性終點評估和替代性終點評估
  • 替代性終點這個生物標記的優點
  • 替代性終點這個生物標記的缺點
  • 生物標記的驗證方法

第3章 神經退化性疾病的生物標記

第4章 輕度認知障礙和老年癡呆症

  • 與老年癡呆症關係為何
  • 是輕度認知障礙還是老年癡呆症
  • 老年癡呆症的生物標記和候補
    • 腦脊髓液分析與血漿分析
    • 目前的生物標記
    • 磷脂質生物標記
    • 核苷酸多態型和預約脂蛋白
    • 睪酮(睪丸激素)和荷爾蒙層級
  • Dr. Howard Federoff的採訪
  • Dr. Jens Wendland 的採訪

第5章 診斷用生物標記

  • Atlantic Biomarkers:研究的背景
  • 生物標記的質譜分析化驗
  • 醫療的影響
  • Dr. Jens Wendland的採訪
    • 企業概要
    • 神經生物標記研究
    • 質譜分析為基礎化驗

第6章 調查結果

第7章 臨床實驗和開發平台資訊


關於Cambridge Healthcare Institute



Biomarkers in Alzheimer's Disease is focused on the biomarker identification and development in patients with Alzheimer's Disease. As a spin-off of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the Alzheimer's Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Alzheimer's Disease, Biomarkers in Alzheimer's Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:

  • Dr. Jens Wendland, Head of Neuroscience Genetics, Precision Medicine, PharmaTherapeutics, Pfizer Worldwide R&D
  • Dr. Howard J. Federoff, Executive Vice President for Health Sciences, Georgetown University
  • Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers

Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

To add even more to the robustness of this report, Insight Pharma Reports also garnered a table of clinical trial information and pipeline data related to Alzheimer's Disease. This table features companies, targets, clinical phases, and brief target/product descriptions.

Table of Contents

Executive Summary

CHAPTER 1: The Focus of this Report

CHAPTER 2: Biomarkers and Their Clinical Utility

  • What are Biomarkers?
  • Advantages of Biomarkers
  • Clinical Endpoints vs. Surrogate Endpoints
  • Advantages of Biomarkers as Surrogate Endpoints
  • Disadvantages to Biomarkers as Surrogate Endpoints
  • How are Biomarkers Validated?

CHAPTER 3: Biomarkers in Neurodegenerative Disorders

CHAPTER 4: Mild Cognitive Impairment and Alzheimer's Disease

  • How is it Related to Alzheimer's Disease?
  • Conflicting Evidence: Mild Cognitive Impairment or Alzheimer's Disease?
  • Biomarkers and Candidates for Alzheimer's Disease
    • Cerebrospinal fluid Analysis vs. Plasma Analysis
    • Current Biomarkers
    • Phospholipid Biomarkers
    • Single Nucleotide Polymorphisms and Apolipoprotein E
    • Testosterone and Hormone Levels
  • Interview with Dr. Howard Federoff
  • Interview with Dr. Jens Wendland

CHAPTER 5: Biomarkers for Diagnostics

  • Atlantic Biomarkers: Research Background
  • Mass-Spectrometry Assays for Biomarkers
  • Impact on Healthcare
  • Interview with Dr. Andreas Jeromin
    • Company Background
    • Neurobiomarker Research
    • Mass Spectrometry-Based Assays

CHAPTER 6: Survey Results

CHAPTER 7: Clinical Trials and Pipeline Information


About Cambridge Healthtech Institute

Tables and Figures

Back to Top